{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:13:52Z","timestamp":1784628832126,"version":"3.55.0"},"reference-count":151,"publisher":"Elsevier","isbn-type":[{"value":"9780443296383","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.irn.2024.07.005","type":"book-chapter","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T20:52:40Z","timestamp":1729371160000},"page":"213-281","source":"Crossref","is-referenced-by-count":4,"title":["Sodium oxybate: A comprehensive review of efficacy and safety in the treatment of alcohol withdrawal syndrome and alcohol dependence"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2024.07.005_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/jcp.0b013e31815a2542","article-title":"Relative abuse liability of \u03b3-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users","volume":"27","author":"Abanades","year":"2007","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1196\/annals.1369.065","article-title":"Hydroxybutyrate (GHB) in humans: Pharmacodynamics and pharmacokinetics","volume":"1074","author":"Abanades","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2024.07.005_bib3","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1073\/pnas.1204376109","article-title":"4 GABAA receptors are high-affinity targets for -hydroxybutyric acid (GHB)","volume":"109","author":"Absalom","year":"2012","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/bs.irn.2024.07.005_bib4","first-page":"1596","article-title":"Gamma-hydroxybutyric acid (GHB) in the treatment of alcohol withdrawal syndrome: A randomized comparative study versus benzodiazepine","volume":"23","author":"Addolorato","year":"1999","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00002826-199901000-00011","article-title":"A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: Utility of diazepam administration","volume":"22","author":"Addolorato","year":"1999","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/oxfordjournals.alcalc.a008160","article-title":"An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group","volume":"31","author":"Addolorato","year":"1996","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.07.005_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0376-8716(98)00094-5","article-title":"Gamma-hydroxybutyric acid in the treatment of alcoholism: Dosage fractioning utility in non-responder alcoholic patients","volume":"53","author":"Addolorato","year":"1998","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.07.005_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14740338.2020.1709821","article-title":"Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects","volume":"19","author":"Addolorato","year":"2020","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/bs.irn.2024.07.005_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1530-0277.1994.tb00053.x","article-title":"Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: Preliminary findings","volume":"18","author":"Adinoff","year":"1994","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib10","series-title":"Alcohol abuse and liver disease","first-page":"55","article-title":"Mechanisms of alcohol toxicity","author":"Aithal","year":"2015"},{"key":"10.1016\/bs.irn.2024.07.005_bib11","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005063.pub3","article-title":"Benzodiazepines for alcohol withdrawal","author":"Amato","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/bs.irn.2024.07.005_bib12","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/ADM.0000000000000992","article-title":"Pharmacotherapies for adults with alcohol use disorders: A systematic review and network meta-analysis","volume":"16","author":"Bahji","year":"2022","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/bs.irn.2024.07.005_bib13","first-page":"15853","article-title":"Comparative efficacy and safety of pharmacotherapies for alcohol withdrawal: A systematic review and network meta\u2010analysis","author":"Bahji","year":"2022","journal-title":"Addiction"},{"key":"10.1016\/bs.irn.2024.07.005_bib14","first-page":"9","article-title":"Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model","volume":"10","author":"Bania","year":"2003"},{"key":"10.1016\/bs.irn.2024.07.005_bib15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.sleep.2017.05.008","article-title":"GHB levels in breast milk of women with narcolepsy with cataplexy treated with sodium oxybate","volume":"36","author":"Barker","year":"2017","journal-title":"Sleep Medicine"},{"key":"10.1016\/bs.irn.2024.07.005_bib16","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bcp.2013.10.028","article-title":"GHB receptor targets in the CNS: Focus on high-affinity binding sites","volume":"87","author":"Bay","year":"2014","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002130050092","article-title":"Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB)","volume":"127","author":"Beardsley","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0091270002239707","article-title":"The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects","volume":"43","author":"Borgen","year":"2003","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib19","first-page":"4654","article-title":"Clinical applications of sodium oxybate (GHB): From narcolepsy to alcohol withdrawal syndrome","volume":"19","author":"Busard\u00f2","year":"2015","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1016\/bs.irn.2024.07.005_bib20","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.forsciint.2016.02.020","article-title":"Determination of GHB levels in breast milk and correlation with blood concentrations","volume":"265","author":"Busard\u00f2","year":"2016","journal-title":"Forensic Science International"},{"key":"10.1016\/bs.irn.2024.07.005_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1570159X13666141210215423","article-title":"GHB pharmacology and toxicology: Acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome","volume":"13","author":"Busard\u00f2","year":"2015","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(02)00340-X","article-title":"Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: An open randomized comparative study","volume":"70","author":"Caputo","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.07.005_bib23","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.euroneuro.2007.04.008","article-title":"Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: An open randomised comparative study","volume":"17","author":"Caputo","year":"2007","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.euroneuro.2010.12.005","article-title":"Sodium oxybate in maintaining alcohol abstinence in alcoholic patients with and without psychiatric comorbidity","volume":"21","author":"Caputo","year":"2011","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib25","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1177\/0269881108094620","article-title":"Incidence of craving for and abuse of gamma-hydroxybutyric acid (GHB) in different populations of treated alcoholics: An open comparative study","volume":"23","author":"Caputo","year":"2009","journal-title":"Journal of Psychopharmacology (Oxford)"},{"key":"10.1016\/bs.irn.2024.07.005_bib26","first-page":"1315","article-title":"Novel strategies to treat alcohol dependence with sodium oxybate according to clinical practice","volume":"19","author":"Caputo","year":"2015","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1016\/bs.irn.2024.07.005_bib27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40263-014-0183-1","article-title":"Sodium oxybate in the treatment of alcohol withdrawal syndrome: A randomized double-blind comparative study versus oxazepam. The GATE 1 trial","volume":"28","author":"Caputo","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.irn.2024.07.005_bib28","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(02)01502-9","article-title":"Central effects of 1,4-butanediol are mediated by GABA(B) receptors via its conversion into gamma-hydroxybutyric acid","volume":"441","author":"Carai","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.brainresprot.2005.04.001","article-title":"Withdrawal syndrome from \u03b3-hydroxybutyric acid (GHB) and 1,4-butanediol (1,4-BD) in Sardinian alcohol-preferring rats","volume":"15","author":"Carai","year":"2005","journal-title":"Brain Research Protocols"},{"key":"10.1016\/bs.irn.2024.07.005_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.04.012","article-title":"Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem\u00ae): Differences in characteristics and misuse","volume":"104","author":"Carter","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.07.005_bib31","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1038\/sj.npp.1301146","article-title":"Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB","volume":"31","author":"Carter","year":"2006","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib32","first-page":"m3934","article-title":"Treatment interventions to maintain abstinence from alcohol in primary care: Systematic review and network meta-analysis","author":"Cheng","year":"2020","journal-title":"BMJ (Clinical Research ed.)"},{"key":"10.1016\/bs.irn.2024.07.005_bib33","unstructured":"CMDh. (2021). List of safety concerns per approved Risk Management Plan (RMP) of active substances per product. Retrieved on May, 4, 2022 https:\/\/www.hma.eu\/human-medicines\/cmdh\/pharmacovigilance\/rmp.html."},{"key":"10.1016\/bs.irn.2024.07.005_bib34","first-page":"197","author":"Colombo","year":"1998","journal-title":"Gamma-hydroxybutyric acid intake in ethanol-preferring sP and -nonpreferring sNP rats"},{"key":"10.1016\/bs.irn.2024.07.005_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079062","article-title":"\u03b3-Hydroxybutyric acid (GHB) is not an agonist of extrasynaptic GABAA receptors","volume":"8","author":"Connelly","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.irn.2024.07.005_bib36","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00213-001-0951-8","article-title":"Effects of the putative antagonist NCS382 on the behavioral pharmacological actions of gammahydroxybutyrate in mice","volume":"160","author":"Cook","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib37","unstructured":"Court of Justice of the European Union. (2024). Judgment of the Court in Case C-291\/22 P | D & A Pharma v Commission and EMA. Available at https:\/\/curia.europa.eu\/jcms\/upload\/docs\/application\/pdf\/2024\u201303\/cp240046en.pdf accessed on April 21, 2024."},{"key":"10.1016\/bs.irn.2024.07.005_bib38","unstructured":"D&A Pharma. (2018). Alcover-sirup product information. Available at https:\/\/www.da-pharma.com\/wp-content\/uploads\/2022\/02\/Alcover_Sirup_summery-characteristics.pdf accessed on April 15, 2024."},{"key":"10.1016\/bs.irn.2024.07.005_bib39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000333022","article-title":"Gamma-hydroxybutyrate detoxification by titration and tapering","volume":"18","author":"de Jong","year":"2012","journal-title":"European Addiction Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib40","first-page":"111","article-title":"Gamma-hydroxybutyric acid induced suppression and prevention of alcohol withdrawal syndrome and relief of craving in alcohol-dependent patients","volume":"7","author":"Di Bello","year":"1995","journal-title":"Alcologia"},{"key":"10.1016\/bs.irn.2024.07.005_bib41","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/j.sleep.2013.11.741","article-title":"Evaluation of drug\u2013drug interactions of sodium oxybate with divalproex: Results from a pharmacokinetic\/pharmacodynamic study","volume":"14","author":"Eller","year":"2013","journal-title":"Sleep Medicine"},{"key":"10.1016\/bs.irn.2024.07.005_bib42","unstructured":"European Medicines Agency. (2006). EPAR Xyrem - Scientific discussion. Retrieved on May 5, 2022 from https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/xyrem-epar-scientific-discussion_en.pdf."},{"key":"10.1016\/bs.irn.2024.07.005_bib43","unstructured":"European Medicines Agency. (2007). Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. CHMP\/EWP\/2459\/02. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_en.pdf Accessed March 5, 2021, b January 2021."},{"key":"10.1016\/bs.irn.2024.07.005_bib44","unstructured":"European Medicines Agency. (2010a). Guideline on the development of medicinal products for the treatment of alcohol dependence. EMA\/CHMP\/EWP\/20097\/2008. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-development-medicinal-products-treatment-alcohol-dependence_en.pdf Accessed March 4, 2021, a."},{"key":"10.1016\/bs.irn.2024.07.005_bib45","unstructured":"European Medicines Agency. (2010b). Overview of comments received on the draft guideline on the development of medicinal products for the treatment of alcohol dependence (CHMP\/EWP\/20097\/08). Retrieved on May 6, 2022 from https:\/\/www.ema.europa.eu\/en\/documents\/other\/overview-comments-received-draft-guideline-development-medicinal-products-treatment-alcohol\/ewp\/20097\/08_en.pdf."},{"key":"10.1016\/bs.irn.2024.07.005_bib46","unstructured":"European Medicines Agency. (2016). Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of PRAC meeting on 10\u201313 May 2016. Retrieved on May 5, 2022 from https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-10\u201313-may-2016_en.pdf."},{"key":"10.1016\/bs.irn.2024.07.005_bib47","unstructured":"European Medicines Agency. (2017a). Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the meeting on 6\u20139 June 2017. Retrieved on May 5, 2022 from https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-6\u20139-june-2017_en.pdf."},{"key":"10.1016\/bs.irn.2024.07.005_bib48","unstructured":"European Medicines Agency. (2017b). Assessment report - Alcover (granules in sachet) - Procedure EMEA\/H\/A-29(4)\/1451. d."},{"key":"10.1016\/bs.irn.2024.07.005_bib49","unstructured":"European Medicines Agency. (2017c). Questions and answers on Alcover granules (sodium oxybate 750, 1250 and 1750 mg) - EMA\/833763\/2017. Available at https:\/\/www.ema.europa.eu\/en\/documents\/referral\/alcover-article-294-referral-questions-and-answers-alcover-granules-sodium-oxybate-750\u20131250-and-1750-mg_en.pdf Last Access on April 22, 2024."},{"key":"10.1016\/bs.irn.2024.07.005_bib50","unstructured":"European Medicines Agency. (2018). Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of PRAC meeting on 14\u201317 May 2018. Retrieved on May 5, 2022 from https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-14\u201317-may-2018_en.pdf."},{"key":"10.1016\/bs.irn.2024.07.005_bib51","unstructured":"European Medicines Agency. (2019a). Guideline on the investigation of subgroups in confirmatory clinical trials. EMA\/CHMP\/539146\/2013. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-subgroups-confirmatory-clinical-trials_en.pdf Accessed March 5, 2021."},{"key":"10.1016\/bs.irn.2024.07.005_bib52","unstructured":"European Medicines Agency. (2019b). Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of PRAC meeting on 13\u201316 May 2019. Retrieved on May 5, 2022 from https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-13\u201316-may-2019_en.pdf."},{"key":"10.1016\/bs.irn.2024.07.005_bib53","unstructured":"European Medicines Agency. (2020a). Assessment report - Hopveus - Procedure No. EMEA\/H\/C\/004962\/0000. Available at https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/hopveus-epar-refusal-public-assessment-report_en.pdf accessed on April 30, 2024."},{"key":"10.1016\/bs.irn.2024.07.005_bib54","unstructured":"European Medicines Agency. (2020b). Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the meeting on 11 \u2013 14 May 2020. Retrieved on May 5, 2022 from https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-11\u201314-may-2020_en.pdf."},{"key":"10.1016\/bs.irn.2024.07.005_bib55","unstructured":"European Medicines Agency. (2021). Pharmacovigilance Risk Assessment Committee (PRAC). Minutes for the meeting on 03\u201306 May 2021. Retrieved on May 5, 2022 from https:\/\/www.ema.europa.eu\/en\/documents\/minutes\/minutes-prac-meeting-3\u20136-may-2021_.pdf."},{"key":"10.1016\/bs.irn.2024.07.005_bib56","unstructured":"FDA. (2005). Estimating the maximum starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Retrieved on May 5, 2022 from https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers 30."},{"key":"10.1016\/bs.irn.2024.07.005_bib57","unstructured":"FDA. (2015). Alcoholism: Developing Drugs for Treatment Guidance for Industry. Available at: https:\/\/www.fda.gov\/files\/drugs\/published\/Alcoholism---Developing-Drugs-for-Treatment.pdf Accessed March 5, 2021 17."},{"key":"10.1016\/bs.irn.2024.07.005_bib58","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s002280050113","article-title":"Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid","volume":"50","author":"Ferrara","year":"1996","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2125.1992.tb04129.x","article-title":"Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses","volume":"34","author":"Ferrara","year":"1992","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2016.00114","article-title":"Potentiation of gamma aminobutyric acid receptors (GABAAR) by ethanol: How are inhibitory receptors affected?","volume":"10","author":"F\u00f6rstera","year":"2016","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/bs.irn.2024.07.005_bib61","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S0140-6736(89)90842-8","article-title":"Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome","author":"Gallimberti","year":"1989","journal-title":"Lancet 2"},{"key":"10.1016\/bs.irn.2024.07.005_bib62","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/npp.1993.45","article-title":"Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome","volume":"9","author":"Gallimberti","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib63","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1530-0277.1992.tb00658.x","article-title":"Gamma-hydroxybutyric acid in the treatment of alcohol dependence: A double-blind study","volume":"16","author":"Gallimberti","year":"1992","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.846983","article-title":"Toxicological characterization of GHB as a performance-enhancing drug","volume":"13","author":"Giorgetti","year":"2022","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.005_bib65","doi-asserted-by":"crossref","first-page":"378","DOI":"10.15288\/jsad.2015.76.378","article-title":"Nosologic comparisons of DSM-IV and DSM-5 alcohol and drug use disorders: Results from the national epidemiologic survey on alcohol and related conditions\u2013III","volume":"76","author":"Goldstein","year":"2015","journal-title":"Journal of Studies on Alcohol and Drugs"},{"key":"10.1016\/bs.irn.2024.07.005_bib66","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-009-1477-8","article-title":"Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons","volume":"204","author":"Goodwin","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib67","article-title":"Intravenous self-administration of gamma-hydroxybutyrate (GHB) in baboons","author":"Goodwin","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.07.005_bib68","first-page":"556","article-title":"Childhood psychiatric disorders as risk factor for subsequent substance abuse: A meta-analysis","volume":"56","author":"Groenman","year":"2017","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.005_bib69","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib70","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.alcohol.2011.08.008","article-title":"Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: Empirically derived predictors of drinking outcomes during treatment","volume":"46","author":"Gueorguieva","year":"2012","journal-title":"Alcohol (Fayetteville, N. Y.)"},{"key":"10.1016\/bs.irn.2024.07.005_bib71","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1530-0277.2010.01369.x","article-title":"Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the combine study: Baseline trajectories of drinking in combine","volume":"35","author":"Gueorguieva","year":"2011","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.04.024","article-title":"Drug-drug interactions in the treatment for alcohol use disorders: A comprehensive review","volume":"133","author":"Guerzoni","year":"2018","journal-title":"Pharmacological Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib73","unstructured":"Guiraud, J., 2023. Sodium oxybate for the treatment of alcohol dependence, University of Amsterdam. ed, Available at https:\/\/hdl.handle.net\/11245.1\/ad0b0a9e-e28c-432d-81a9-ccdf39b190f8, last access on December 21, 2023."},{"key":"10.1016\/bs.irn.2024.07.005_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/02698811221104063","article-title":"Sodium oxybate for the maintenance of abstinence in alcohol dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial","author":"Guiraud","year":"2022","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/alcalc\/agac070","article-title":"Sodium oxybate for alcohol dependence: A network meta-regression analysis considering population severity at baseline and treatment duration","author":"Guiraud","year":"2023","journal-title":"Alcohol and Alcoholism agac070"},{"key":"10.1016\/bs.irn.2024.07.005_bib76","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euroneuro.2021.06.003","article-title":"Treating alcohol dependence with an abuse and misuse deterrent formulation of sodium oxybate: Results of a randomised, double-blind, placebo-controlled study","volume":"52","author":"Guiraud","year":"2021","journal-title":"European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib77","first-page":"187","article-title":"Substitution therapy for patients with alcohol dependence: Mechanisms of action and efficacy","author":"Guiraud","year":"2024","journal-title":"International Review of Neurobiology 175"},{"key":"10.1016\/bs.irn.2024.07.005_bib78","unstructured":"ICH. (1998). International conference on harmonisation; guidance on statistical principles for clinical trials; availability--FDA. Notice. Fed Regist 63, 49583\u201349598."},{"key":"10.1016\/bs.irn.2024.07.005_bib79","unstructured":"ICH. (2016). M4E(R2) - Common technical document for the registration of pharmaceuticals for human use \u2013 Efficacy (EMA\/CPMP\/ICH\/2887\/1999)."},{"key":"10.1016\/bs.irn.2024.07.005_bib80","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1749-6632.2002.tb04186.x","article-title":"Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: Assessment of the sedative and rewarding effects of GHB","volume":"965","author":"Itzhak","year":"2002","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2024.07.005_bib81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1037\/a0031692","article-title":"Comparative abuse liability of GHB and ethanol in humans","volume":"21","author":"Johnson","year":"2013","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib82","unstructured":"Kamal, R. M. (2016). The detoxification approach for patients with GHB dependence. [S.l.: s.n.] - Retrieved on May 5, 2022 from https:\/\/repository.ubn.ru.nl\/bitstream\/handle\/2066\/151486\/151486.pdf?sequence=1."},{"key":"10.1016\/bs.irn.2024.07.005_bib83","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000443173","article-title":"The neurobiological mechanisms of gamma-hydroxybutyrate dependence and withdrawal and their clinical relevance: A review","volume":"73","author":"Kamal","year":"2016","journal-title":"Neuropsychobiology"},{"key":"10.1016\/bs.irn.2024.07.005_bib84","unstructured":"Kaplan, W., Wirtz, V.J., Mantel-Teeuwisse, A., Stolk, P., Duthey, B., & Laing, R.. (2013). Priority medicines for Europe and the World - 2013 Update."},{"key":"10.1016\/bs.irn.2024.07.005_bib85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40261-013-0158-x","article-title":"Sodium oxybate: A review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence","volume":"34","author":"Keating","year":"2014","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/bs.irn.2024.07.005_bib86","first-page":"83","article-title":"Gamma-hydroxybutyric acid in the treatment of alcohol withdrawal syndrome in patients admitted to hospital","volume":"30","author":"Korninger","year":"2003","journal-title":"Acta Medica Austriaca"},{"key":"10.1016\/bs.irn.2024.07.005_bib87","doi-asserted-by":"crossref","DOI":"10.1111\/j.1530-0277.2007.00344.x","article-title":"Antiglutamatergic strategies for ethanol detoxification: Comparison with placebo and diazepam","author":"Krupitsky","year":"2007","journal-title":"Alcoholism: Clinical and Experimental Research 0, 070212174136008-???"},{"key":"10.1016\/bs.irn.2024.07.005_bib88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0028-3908(64)90074-7","article-title":"Sodium 4-hydroxybutyrate","volume":"3","author":"Laborit","year":"1964","journal-title":"International Journal of Neuropharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib89","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s11469-013-9465-y","article-title":"Gender congruence moderates beliefs about the causes of alcohol dependence and major depression","volume":"12","author":"Lale","year":"2014","journal-title":"International Journal of Mental Health and Addiction"},{"key":"10.1016\/bs.irn.2024.07.005_bib90","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.ALC.0000117831.17383.72","article-title":"Psychiatric comorbidity in treatment-seeking alcoholics: The role of childhood trauma and perceived parental dysfunction","volume":"28","author":"Langeland","year":"2004","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib91","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.pnpbp.2007.09.021","article-title":"New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications","volume":"32","author":"Leggio","year":"2008","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.005_bib92","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006266.pub2","article-title":"Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses","author":"Leone","year":"2010","journal-title":"Cochrane Database Syst Rev CD006266"},{"key":"10.1016\/bs.irn.2024.07.005_bib93","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/bcp.12863","article-title":"Pharmacokinetics and pharmacodynamics of \u03b3-hydroxybutyrate in healthy subjects: Effects of \u03b3-hydroxybutyrate in healthy subjects","volume":"81","author":"Liechti","year":"2016","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib94","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/acer.12197","article-title":"The placebo effect in clinical trials for alcohol dependence: An exploratory Aanalysis of 51 naltrexone and acamprosate studies","volume":"37","author":"Litten","year":"2013","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib95","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1369-1600.2012.00454.x","article-title":"Medications development to treat alcohol dependence: A vision for the next decade: Medications development","volume":"17","author":"Litten","year":"2012","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.07.005_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008502.pub5","article-title":"Baclofen for alcohol withdrawal","author":"Liu","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/bs.irn.2024.07.005_bib97","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jhm.928","article-title":"Treating alcohol withdrawal with oral baclofen: A randomized, double-blind, placebo-controlled trial","volume":"6","author":"Lyon","year":"2011","journal-title":"Journal of Hospital Medicine"},{"key":"10.1016\/bs.irn.2024.07.005_bib98","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000455841","article-title":"German guidelines on screening, diagnosis and treatment of alcohol use disorders","volume":"23","author":"Mann","year":"2017","journal-title":"European Addiction Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib99","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","article-title":"The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis","volume":"28","author":"Mann","year":"2004","journal-title":"Alcoholism: Clinical & Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib100","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: Review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib101","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3280\/mis46-2016oa4626","article-title":"La terapia farmacologia dell\u2019alcolismo: Il sodio oxibato (acido gamma-idrossibutirrico- GHB) farmaco anti-alcol approvato dall\u2019organismo regolatorio italiano per la pratica clinica. Parte III","author":"Manzato","year":"2017","journal-title":"Mission"},{"key":"10.1016\/bs.irn.2024.07.005_bib102","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/02791072.2001.10400478","article-title":"Long-term therapy using GHB (sodium gamma hydroxybutyrate) for treatment-resistant chronic alcoholics","volume":"33","author":"Maremmani","year":"2001","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/bs.irn.2024.07.005_bib103","first-page":"236","article-title":"Actions and interactions with alcohol of drugs on psychomotor skills: Comparison of diazepam and gamma-hydroxybutyric acid","volume":"234","author":"Mattila","year":"1978","journal-title":"Archives Internationales de Pharmacodynamie et de Therapie"},{"key":"10.1016\/bs.irn.2024.07.005_bib104","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jama.1997.03550020076042","article-title":"Pharmacological management of alcohol withdrawal: A meta-analysis and evidence-based practice guideline","volume":"278","author":"Mayo-Smith","year":"1997","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2024.07.005_bib105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/jat\/23.5.301","article-title":"Analysis of gamma-hydroxybutyrate (GHB) in urine by gas chromatography-mass spectrometry","volume":"23","author":"McCusker","year":"1999","journal-title":"Journal of Analytical Toxicology"},{"key":"10.1016\/bs.irn.2024.07.005_bib106","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005064.pub3","article-title":"Anticonvulsants for alcohol withdrawal","author":"Minozzi","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/bs.irn.2024.07.005_bib107","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0741-8329(99)00093-2","article-title":"Gamma-hydroxybutyric acid and alcohol-related syndromes","volume":"20","author":"Moncini","year":"2000","journal-title":"Alcohol (Fayetteville, N. Y.)"},{"key":"10.1016\/bs.irn.2024.07.005_bib108","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/00952990.2017.1339055","article-title":"Effect of chronic \u03b3-hydroxybutyrate (GHB) administration on GHB toxicokinetics and GHB-induced respiratory depression","volume":"43","author":"Morse","year":"2017","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/bs.irn.2024.07.005_bib109","unstructured":"National Institute on Alcohol Abuse and Alcoholism. (2021). Alcohol use disorder: A comparison between DSM-IV and DSM-5. Available at https:\/\/www.niaaa.nih.gov\/sites\/default\/files\/publications\/AUD_A_Comparison.pdf Last Access 3 January 2023 2."},{"key":"10.1016\/bs.irn.2024.07.005_bib110","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/00952990701315046","article-title":"Gamma-hydroxybutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: An open study vs. diazepam","volume":"33","author":"Nava","year":"2007","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/bs.irn.2024.07.005_bib111","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/02791072.2006.10399846","article-title":"Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions","volume":"38","author":"Nava","year":"2006","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/bs.irn.2024.07.005_bib112","unstructured":"Nice. (2011). Alcohol-use disorders: Diagnosis, assessment and management of harmful drinking and alcohol dependence - Appendix 17d Pharmacological Interventions Forest Plots. Available at: https:\/\/www.nice.org.uk\/guidance\/cg115\/evidence\/appendix-17d-pharmacological-interventions-forest-plots-pdf-4911242584 Accessed October 10, 2021."},{"key":"10.1016\/bs.irn.2024.07.005_bib113","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/alcalc\/37.1.67","article-title":"Double-blind controlled trial of gamma-hydroxybutyrate and clomethiazole in the treatment of alcohol withdrawal","volume":"37","author":"Nimmerrichter","year":"2002","journal-title":"Alcohol and Alcoholism (Oxford, Oxfordshire)"},{"key":"10.1016\/bs.irn.2024.07.005_bib114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13041-017-0325-8","article-title":"Role of GABAA receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model","volume":"10","author":"Olsen","year":"2017","journal-title":"Molecular Brain"},{"key":"10.1016\/bs.irn.2024.07.005_bib115","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/jama.1994.03520220035028","article-title":"Common mental disorders and disability across cultures: Results from the WHO collaborative study on psychological problems in general health care","volume":"272","author":"Ormel","year":"1994","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/bs.irn.2024.07.005_bib116","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00265954","article-title":"Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers","volume":"45","author":"Palatini","year":"1993","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib117","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s40263-014-0163-5","article-title":"Inpatient management of acute alcohol withdrawal syndrome","volume":"28","author":"Perry","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/bs.irn.2024.07.005_bib118","unstructured":"Plinius Maior Society, 1994. Guidelines on evaluation of treatment of alcohol dependence."},{"key":"10.1016\/bs.irn.2024.07.005_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108536","article-title":"Evaluation of the course and treatment of Alcohol Withdrawal Syndrome with the Clinical Institute Withdrawal Assessment for Alcohol - Revised: A systematic review-based meta-analysis","volume":"220","author":"Prib\u00e9k","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/bs.irn.2024.07.005_bib120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1192\/bjp.177.2.181","article-title":"In-patient detoxification after GHB dependence","volume":"177","author":"Price","year":"2000","journal-title":"The British Journal of Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.005_bib121","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/bcp.12632","article-title":"Pharmacodynamic interactions of a solid formulation of sodium oxybate and ethanol in healthy volunteers","volume":"80","author":"Pross","year":"2015","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib122","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1196\/annals.1369.055","article-title":"Evaluation for the withdrawal syndrome from -hydroxybutyric acid (GHB), -butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines","volume":"1074","author":"Quang","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1016\/bs.irn.2024.07.005_bib123","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1124\/jpet.106.113886","article-title":"Pharmacokinetics and pharmacodynamics of -hydroxybutyric acid during tolerance in rats: Effects on extracellular dopamine","volume":"320","author":"Raybon","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/bs.irn.2024.07.005_bib124","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1360-0443.2010.02899.x","article-title":"The relation between different dimensions of alcohol consumption and burden of disease: An overview","volume":"105","author":"Rehm","year":"2010","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/bs.irn.2024.07.005_bib125","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/adb.12646","article-title":"Alcohol dependence and very high risk level of alcohol consumption: A life-threatening and debilitating disease","volume":"23","author":"Rehm","year":"2018","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.07.005_bib126","article-title":"Alcohol consumption, alcohol dependence and attributable burden of disease in Europe","author":"Rehm","year":"2012","journal-title":"Centre for Addiction and Mental Health"},{"key":"10.1016\/bs.irn.2024.07.005_bib127","article-title":"Acamprosate for alcohol dependence","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Database of Systematic Reviews CD004332"},{"key":"10.1016\/bs.irn.2024.07.005_bib128","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.3390\/nu13093173","article-title":"Alcohol and cancer: Epidemiology and biological mechanisms","volume":"13","author":"Rumgay","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/bs.irn.2024.07.005_bib129","first-page":"881","article-title":"Pharmacotherapies for alcohol abuse","volume":"81","author":"Saitz","year":"1997","journal-title":"Medical Clinics"},{"key":"10.1016\/bs.irn.2024.07.005_bib130","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1528-1167.2009.02426.x","article-title":"Alcohol consumption, unprovoked seizures, and epilepsy: A systematic review and meta-analysis: Alcohol & epilepsy","volume":"51","author":"Samokhvalov","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/bs.irn.2024.07.005_bib131","doi-asserted-by":"crossref","DOI":"10.1111\/acer.14670","article-title":"Baseline severity and the prediction of placebo response in clinical trials for alcohol dependence: A meta\u2010regression analysis to develop an enrichment strategy","author":"Scherrer","year":"2021","journal-title":"Alcoholism, Clinical and Experimental Research"},{"key":"10.1016\/bs.irn.2024.07.005_bib132","article-title":"Alcohol use disorders and associated chronic disease \u2013 A national retrospective cohort study from France","volume":"18","author":"Schwarzinger","year":"2017","journal-title":"BMC Public Health"},{"key":"10.1016\/bs.irn.2024.07.005_bib133","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1176\/appi.ajp.2020.20050610","article-title":"The World Health Organization risk drinking levels measure of alcohol consumption: Prevalence and health correlates in nationally representative surveys of U.S. adults, 2001-2002 and 2012-2013","volume":"178","author":"Shmulewitz","year":"2021","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/bs.irn.2024.07.005_bib134","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14656566.2014.863278","article-title":"Sodium oxybate in the treatment of alcohol dependence: From the alcohol withdrawal syndrome to the alcohol relapse prevention","volume":"15","author":"Skala","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/bs.irn.2024.07.005_bib135","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1152\/physrev.00013.2008","article-title":"Alcoholism: A systems approach from molecular physiology to addictive behavior","volume":"89","author":"Spanagel","year":"2009","journal-title":"Physiological Reviews"},{"key":"10.1016\/bs.irn.2024.07.005_bib136","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.jcp.0000237944.57893.28","article-title":"GHB and ethanol effects and interactions in humans.","volume":"26","author":"Thai","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib137","unstructured":"UCB. (2022). Xyrem - Product information. Available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xyrem-epar-product-information_en.pdf accessed April 14, 2024."},{"key":"10.1016\/bs.irn.2024.07.005_bib138","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/adb.12645","article-title":"Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level","volume":"23","author":"van den Brink","year":"2018","journal-title":"Addiction Biology"},{"key":"10.1016\/bs.irn.2024.07.005_bib139","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/alcalc\/agt061","article-title":"Efficacy of as-needed nalmefene in alcohol-dependent patients with at least a high drinking risk level: Results from a subgroup analysis of two randomized controlled 6-month studies","volume":"48","author":"van den Brink","year":"2013","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/bs.irn.2024.07.005_bib140","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/toxsci\/kfg079","article-title":"Characterization of the pharmacokinetic and pharmacodynamic interaction between gamma-hydroxybutyrate and ethanol in the rat","volume":"73","author":"Van Sassenbroeck","year":"2003","journal-title":"Toxicological Sciences"},{"key":"10.1016\/bs.irn.2024.07.005_bib141","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5664\/jcsm.27549","article-title":"Safety overview of post-marketing and clinical experience of sodium oxybate (Xyrem): Abuse, misuse, dependence, and diversion","author":"Wang","year":"2009","journal-title":"Journal of Clinical Sleep Medicine 5"},{"key":"10.1016\/bs.irn.2024.07.005_bib142","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00213-004-2079-0","article-title":"Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons","volume":"179","author":"Weerts","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/bs.irn.2024.07.005_bib143","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/acps.12330","article-title":"Mortality and life expectancy of people with alcohol use disorder in Denmark, Finland and Sweden","volume":"131","author":"Westman","year":"2015","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/bs.irn.2024.07.005_bib144","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/oxfordjournals.alcalc.a008326","article-title":"A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale)","volume":"32","author":"Wetterling","year":"1997","journal-title":"Alcohol and Alcoholism"},{"key":"10.1016\/bs.irn.2024.07.005_bib145","unstructured":"WHO, 2014. Gamma-butyrolactone (GBL) - Critical Review Report."},{"key":"10.1016\/bs.irn.2024.07.005_bib146","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Science Advances"},{"key":"10.1016\/bs.irn.2024.07.005_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/S0376-8716(98)00153-7","article-title":"Evaluation of the reinforcing and discriminative stimulus effects of k-hydroxybutyrate in rhesus monkeys","author":"Woolverton","year":"1999","journal-title":"Drug and Alcohol Dependence 7"},{"key":"10.1016\/bs.irn.2024.07.005_bib148","unstructured":"World Health Organization. (2000). International guide for monitoring alcohol consumption and related harm. Retrieved on May 5, 2022 from https:\/\/apps.who.int\/iris\/handle\/10665\/66529."},{"key":"10.1016\/bs.irn.2024.07.005_bib149","unstructured":"World Health Organization. (2012). Gamma-hydroxybutyric acid (GHB) - Critical review report. Retrieved on May 6, 2022 from https:\/\/kipdf.com\/gamma-hydroxybutyric-acid-ghb-critical-review-report-expert-committee-on-drug-de_5ac4e7c91723dd210d0a315e.html."},{"key":"10.1016\/bs.irn.2024.07.005_bib150","unstructured":"World Health Organization. (2018). Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Retrieved on May 5, 2022 from http:\/\/www.who.int\/substance_abuse\/publications\/global_alcohol_report\/en\/."},{"key":"10.1016\/bs.irn.2024.07.005_bib151","unstructured":"World Health Organization. (2019). ICD-11: International classification of diseases (11th revision). Retrieved on May 5, 2022 from https:\/\/icd.who.int\/."}],"container-title":["International Review of Neurobiology","Advances in Alcohol Use Disorder Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000904?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774224000904?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:21:15Z","timestamp":1762230075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774224000904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443296383"],"references-count":151,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2024.07.005","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}